Indinavir concentrations and St John's wort - PubMed (original) (raw)

Clinical Trial

Indinavir concentrations and St John's wort

S C Piscitelli et al. Lancet. 2000.

Erratum in

• Lancet 2001 Apr 14;357(9263):1210

Abstract

St John's wort reduced the area under the curve of the HIV-1 protease inhibitor indinavir by a mean of 57% (SD 19) and decreased the extrapolated 8-h indinavir trough by 81% (16) in healthy volunteers. A reduction in indinavir exposure of this magnitude could lead to the development of drug resistance and treatment failure.

PubMed Disclaimer

Similar articles

• Patients being treated for HIV should avoid St. John's Wort: NIH.
  [No authors listed] [No authors listed] J Am Dent Assoc. 2000 Apr;131(4):439, 442. doi: 10.14219/jada.archive.2000.0195. J Am Dent Assoc. 2000. PMID: 10770006 No abstract available.
• Interaction between indinavir and St. John's wort reported.
  Miller JL. Miller JL. Am J Health Syst Pharm. 2000 Apr 1;57(7):625-6. doi: 10.1093/ajhp/57.7.625. Am J Health Syst Pharm. 2000. PMID: 10768811 No abstract available.
• St. John's wort warning: do not combine with protease inhibitors, NNRTIs.
  James JS. James JS. AIDS Treat News. 2000 Feb 18;(No 337):3-5. AIDS Treat News. 2000. PMID: 11367207
• The emerging recognition of herb-drug interactions with a focus on St. John's wort (Hypericum perforatum).
  Markowitz JS, DeVane CL. Markowitz JS, et al. Psychopharmacol Bull. 2001 Winter;35(1):53-64. Psychopharmacol Bull. 2001. PMID: 12397870 Review.
• Pharmacokinetic interactions of drugs with St John's wort.
  Zhou S, Chan E, Pan SQ, Huang M, Lee EJ. Zhou S, et al. J Psychopharmacol. 2004 Jun;18(2):262-76. doi: 10.1177/0269881104042632. J Psychopharmacol. 2004. PMID: 15260917 Review.

Cited by

• Flavonoids as CYP3A4 Inhibitors In Vitro.
  Kondža M, Brizić I, Jokić S. Kondža M, et al. Biomedicines. 2024 Mar 13;12(3):644. doi: 10.3390/biomedicines12030644. Biomedicines. 2024. PMID: 38540257 Free PMC article. Review.
• Complementary and alternative medicine use among people living with HIV in Shiraz, Southern Iran.
  Mosavat SH, Pasalar M, Joulaei H, Ameli V, Heydari ST, Mirzazadeh A, Hashempur MH. Mosavat SH, et al. Front Public Health. 2023 Oct 5;11:1206665. doi: 10.3389/fpubh.2023.1206665. eCollection 2023. Front Public Health. 2023. PMID: 37869188 Free PMC article.
• Hypericum perforatum: Traditional uses, clinical trials, and drug interactions.
  Nobakht SZ, Akaberi M, Mohammadpour AH, Tafazoli Moghadam A, Emami SA. Nobakht SZ, et al. Iran J Basic Med Sci. 2022 Sep;25(9):1045-1058. doi: 10.22038/IJBMS.2022.65112.14338. Iran J Basic Med Sci. 2022. PMID: 36246064 Free PMC article. Review.
• Alternatives to rifampicin: A review and perspectives on the choice of strong CYP3A inducers for clinical drug-drug interaction studies.
  Bolleddula J, Gopalakrishnan S, Hu P, Dong J, Venkatakrishnan K. Bolleddula J, et al. Clin Transl Sci. 2022 Sep;15(9):2075-2095. doi: 10.1111/cts.13357. Epub 2022 Jul 25. Clin Transl Sci. 2022. PMID: 35722783 Free PMC article. Review.
• Development and Experimental Validation of Regularized Machine Learning Models Detecting New, Structurally Distinct Activators of PXR.
  Hirte S, Burk O, Tahir A, Schwab M, Windshügel B, Kirchmair J. Hirte S, et al. Cells. 2022 Apr 7;11(8):1253. doi: 10.3390/cells11081253. Cells. 2022. PMID: 35455933 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Ovid Technologies, Inc.